Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development Theresa Visarius will present initial clinical and translational data on the use of IP-001 in solid tumor indications on April 24th in the Clinical Stage Development Companies session.
